ID
12498
Description
Study documentation part: Adverse event. This is a phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS). Principal Investigator PD Dr. Tobias Görge, University Hospital of Münster. EudraCT - Nr. 2012-000108-13.
Keywords
Versions (2)
- 11/24/15 11/24/15 -
- 11/24/15 11/24/15 - Julian Varghese
Uploaded on
November 24, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Riliva_CRF_EudraCT - Nr. 2012-000108-13- Adverse event DRKS00004652
Riliva_CRF_EudraCT - Nr. 2012-000108-13- Adverse event
- StudyEvent: ODM
Similar models
Riliva_CRF_EudraCT - Nr. 2012-000108-13- Adverse event
- StudyEvent: ODM
C0869014 (UMLS CUI [1,2])
C0079809 (UMLS CUI [1,2])